Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

The primary objective is to assess the efficacy of EP-104GI in improving tissue health, as measured by the Eosinophilic Esophagitis Histology Scoring System (“EoEHSS”).

After six months, eligible patients initially dosed with placebo may elect to receive EP-104GI. The primary objective is to assess the efficacy of EP-104GI in improving tissue health, as measured by ...

Eosinophilic gastrointestinal diseases are exponentially more prevalent among patients with atopic diseases compared with the ...

The primary objective is to assess the efficacy of EP-104GI in improving tissue health, as measured by the Eosinophilic Esophagitis Histology Scoring System (“EoEHSS”).

A study published in July 2025 issue of Journal of Allergy and Clinical Immunology Global highlighted persistent challenges ...

People with eosinophilic esophagitis may benefit from managing their diet to control their exposure to trigger foods. Learn more about elimination diets here.

Primary care physicians play a vital role in identifying red flags for rare eosinophilic diseases like HES and EGPA, enabling ...

Dexpramipexole targets eosinophilic inflammation Knopp Biosciences’ investigational, first-in-class drug, dexpramipexole, holds promise for patients with asthma and eosinophil-associated diseases.

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...